CEO Total Pay
$217K
FY2023 Summary Compensation, below median
NKTR FY2023 SEC EDGAR DEF 14A
Nektar Therapeutics CEO pay ratio
The CEO earned $217K in FY2023 against median worker pay of $216,654 · Chemicals & Pharmaceuticals.
- State
- DE
- Filing date
- 2024-04-26
- Industry
- Chemicals & Pharmaceuticals
- Fiscal year
- FY2023
Data updated August 2026
Subscribe to Nektar Therapeutics CEO pay filing updates (RSS)
CEO-to-worker pay ratio
14:1
Below Average (Scale: 0–1000:1)
CEO pay
$217K
Median worker
$216,654
Latest filing FY2023. This company's newest DEF 14A on file is for FY2023, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.
Answer first
Nektar Therapeutics reported a 14:1 CEO-to-worker pay ratio in FY2023 - at or below the Chemicals & Pharmaceuticals median of 42:1 across 168 filers.
Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.
- Pay ratio
- 14:1
- FY2023 disclosed
- CEO total
- $217K
- Summary Compensation Table total
- Median worker
- $216,654
- Dodd-Frank median employee
Ratio bands among Chemicals & Pharmaceuticals peers
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
CEO Compensation Breakdown, FY2023
A component-level pay breakdown is not reported in Nektar Therapeutics's structured SEC pay-ratio disclosure. See our methodology →
Filing-year trail · Nektar Therapeutics
Complete DEF 14A pay-ratio filings for this CIK across FY2021–2023. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).
- Latest ratio
- 14:1
- FY2023
- vs prior FY
- -33:1
- from FY2022 47:1
- CEO $ YoY
- -9.9%
- $217K latest
- Filings shown
- 3
- FY2021–2023
| FY | CEO pay | Δ pay | Median worker | Pay ratio | Δ ratio |
|---|---|---|---|---|---|
| 2021 | $194K | - | $193,581 | 58:1 | - |
| 2022 | $241K | +24% | $240,505 | 47:1 | -11:1 |
| 2023 | $217K | -9.9% | $216,654 | 14:1 | -33:1 |
Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 906709, FY2021–2023. Adjacent-year deltas only.
Industry Comparison - Chemicals & Pharmaceuticals
This Company's Ratio
14:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$217K
Companies in Industry
168
vs. Industry Median
Below
Nektar Therapeutics: near-parity Item 402(u) ratio
Nektar Therapeutics stamps FLOOR · ELITE-MED at 14:1 against $216,654 median worker pay in FY2023. the CEO earned 14× the median employee ($216,654) in FY2023.
At $216,654 median worker pay, the FLOOR stamp is near pay-parity territory under MICRO CEO total.
Pay Ratio
14:1
Below typical
What FY2023 shows for Nektar Therapeutics
Nektar Therapeutics stamps FLOOR · ELITE-MED at 14:1 against $216,654 median worker pay in FY2023. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Nektar Therapeutics's $217K CEO total is at or below the $7.9M industry median CEO pay.
Nektar Therapeutics stamps FLOOR · MICRO · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.
Key Data, FY2023
- Total Compensation
- $217K
- Median Employee Pay
- $216,654
- Pay Ratio
- 14:1
- Filing Date
- 2024-04-26
Company Info
- Ticker
- NKTR
- CIK
- 906709
- Industry
- Chemicals & Pharmaceuticals
- SIC Code
- 2834
- State
- DE
SEC EDGAR DEF 14A for CIK 906709, FY2023. Informational only, not investment advice. Verify on EDGAR.
Read our methodology - how this data is sourced, computed, and verified. Nektar Therapeutics stamps FLOOR · ELITE-MED at 14:1 against $216,654 median worker pay in FY2023.
Read with Nektar Therapeutics
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · MICRO · ELITE-MED.
Verisign Inc/ca · MICRO
ABS(ceo_total_comp) peer at $217K (Δ $542 heavier vs Nektar Therapeutics); MODEST · ELITE-MED vs this page's FLOOR · MICRO · ELITE-MED.
Box Inc · MICRO
ABS(ceo_total_comp) peer at $211K (Δ $5K lighter vs Nektar Therapeutics); PARITY · ELITE-MED vs this page's FLOOR · MICRO · ELITE-MED.
Marine Products Group, LLC · MICRO
ABS(ceo_total_comp) peer at $211K (Δ $6K lighter vs Nektar Therapeutics); FLOOR · LOW-MED vs this page's FLOOR · MICRO · ELITE-MED.
City Office REIT, Inc. · MICRO
ABS(ceo_total_comp) peer at $225K (Δ $8K heavier vs Nektar Therapeutics); FLOOR · ELITE-MED vs this page's FLOOR · MICRO · ELITE-MED.
Chemicals & Pharmaceuticals benchmark
Nektar Therapeutics stamps FLOOR · MICRO · ELITE-MED inside SIC 28 - open the industry median board after the ABS peers.
Pay-ratio rankings · FLOOR
See where FLOOR · MICRO packages sit on the national leaderboard after reading Nektar Therapeutics.
Ratio primer · FLOOR
Nektar Therapeutics's FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Nektar Therapeutics (CIK 906709), FY2023. See our methodology. Aggregated by PlainCEOPay as of August 2026.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.